Nebulizer

AireHealth Announces FDA 510(k) Clearance of Connected Nebulizer for Patients with Respiratory Conditions

Retrieved on: 
Monday, December 7, 2020
Software, Biotechnology, Pharmaceutical, Health, FDA, Medical devices, Technology, Mobile, Wireless, Health care, Medicine, Health sciences, Respiratory therapy, Respiratory therapist, Nebulizer, Food and Drug Administration

AireHealth, an innovative digital health company empowering and improving healthy living through affordable treatments, symptom tracking and early detection of respiratory conditions, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its connected nebulizer.

Key Points: 
  • AireHealth, an innovative digital health company empowering and improving healthy living through affordable treatments, symptom tracking and early detection of respiratory conditions, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its connected nebulizer.
  • In 2021, AireHealth will also add VitalCapacity , a connected spirometer, to its VitalBreath respiratory care platform.
  • AireHealth is pleased to have received 510(k) clearance of our connected nebulizer from the FDA, which will support the creation of an overall ecosystem of connected solutions to treat patients with respiratory conditions.
  • The acquisition has positioned AireHealth to integrate data collection and analysis capabilities into its connected respiratory care platform.

$1.69 Billion Nebulizer Markets by Product Type, Portability, Application, End User - Global Industry Analysis and Growth Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 30, 2020
Medical devices, Health, Medical equipment, Respiratory therapy, Health sciences, Health care, Medicine, Aerosols, Nebulizer, Ventilator, Syringe, Heroin

The "Nebulizer Market Research Report: By Product Type, Portability, Application, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nebulizer Market Research Report: By Product Type, Portability, Application, End User - Global Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This has crippled the global healthcare sector, with inventories of everything, from testing kits and syringes to beds and ventilators, depleting fast.
  • Thus, governments are making an all-out effort to procure all the necessary stuff to make patients comfortable and treat them.
  • In the years to come, the fastest growth in the nebulizer market is set to be witnessed in the Asia-Pacific (APAC) region.

Global Pulmonary Devices Market Forecast to 2027: Increasing Preference of Home Care Products - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 25, 2020
Medical devices, Health, Respiratory therapy, Health sciences, Medicine, Health, Dosage forms, Asthma, Respiratory disease, Pulmonology, Inhaler, Nebulizer, Coronavirus disease, Chronic condition

The global pulmonary devices market,based on type, is segmented into therapeutic devices, consumables and accessories, diagnostic devices, and monitoring devices.

Key Points: 
  • The global pulmonary devices market,based on type, is segmented into therapeutic devices, consumables and accessories, diagnostic devices, and monitoring devices.
  • The therapeutic devices segment held the largest share of the market in 2019, and this growth is ascribed to the increasing demand of inhalers and nebulizers by patients suffering with asthma and chronic obstructive pulmonary disorders.
  • Also, the impact of the COVID-19 crisis is expected to further accelerate the growth of the respiratory devices market.
  • The growth of the pulmonary devices market is attributed to factors such as rising number of COVID-19 cases worldwide and increasing prevalence of respiratory diseases.

Monograph Published by World Scientific Publishing Proves Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer Effective in Treating COVID-19

Retrieved on: 
Wednesday, November 11, 2020
Chemistry, Physical sciences, Medicine, Respiratory therapy, Chemical elements, Reactive nonmetals, Medical equipment, Dosage forms, Nebulizer, Oxygen therapy, Oxygen, Biocompatibility

Developed by Asclepius Meditec, Hydrogen Oxygen Generator with Nebulizer has received the National Innovative Class III medical device certificate by NMPA (Chinese National Medical Products Administration) in 2020, marking another milestone in the history of hydrogen-oxygen medicine.

Key Points: 
  • Developed by Asclepius Meditec, Hydrogen Oxygen Generator with Nebulizer has received the National Innovative Class III medical device certificate by NMPA (Chinese National Medical Products Administration) in 2020, marking another milestone in the history of hydrogen-oxygen medicine.
  • Now, the device has passed compliance tests for medical devices in the EU, including safety, electromagnetic compatibility, biocompatibility, etc.
  • The English digital copy of the monograph was published on October 16.
  • Contact us for Hydrogen Oxygen Generator with Nebulizer: 86-21-5990-1777 ext.

Monograph Published by World Scientific Publishing Proves Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer Effective in Treating COVID-19

Retrieved on: 
Wednesday, November 11, 2020
Chemistry, Physical sciences, Natural sciences, Respiratory therapy, Chemical elements, Reactive nonmetals, Diving medicine, Oxygen, Oxygen therapy, Nebulizer, Hydrogen, Pneumonia

Published by World Scientific Publishing on November 14, 2020, the monograph highlights the effectiveness of Hydrogen Oxygen Generator with Nebulizer in alleviating the symptoms of COVID-19 pneumonia and explained that inhaling the hydrogen-oxygen mixed gas can reduce disease severity and dyspnea in patients with COVID-19 and shorten their length of hospitalization.

Key Points: 
  • Published by World Scientific Publishing on November 14, 2020, the monograph highlights the effectiveness of Hydrogen Oxygen Generator with Nebulizer in alleviating the symptoms of COVID-19 pneumonia and explained that inhaling the hydrogen-oxygen mixed gas can reduce disease severity and dyspnea in patients with COVID-19 and shorten their length of hospitalization.
  • The physical and biological effects of molecular hydrogen indicate that hydrogen-oxygen inhalation therapy for COVID-19 pneumonia is theoretically reasonable and feasible.
  • Founded in 2011, Shanghai Asclepius Meditec is the first company globally to launch clinical research on hydrogen-oxygen medicine.
  • Contact us for Hydrogen Oxygen Generator with Nebulizer:

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

Retrieved on: 
Monday, November 9, 2020
Respiratory therapy, Health sciences, Health, Chronic lower respiratory diseases, Occupational diseases, Dosage forms, Chronic obstructive pulmonary disease, Nebulizer, Forward-looking statement

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE ("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD maintenance treatment.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

LAMIRA®, an eFlow® Technology nebuliser, is the first and only device to deliver Insmed's ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion in the European Union

Retrieved on: 
Monday, November 2, 2020
Health sciences, Dosage forms, Pharmacology, Health care, Amikacin, Breakthrough therapy, Nebulizer, Liposome, eFlow

The LAMIRA Nebuliser System is specifically optimised for the administration of ARIKAYCE, and patented features are included.

Key Points: 
  • The LAMIRA Nebuliser System is specifically optimised for the administration of ARIKAYCE, and patented features are included.
  • "LAMIRA is another great example of a nebuliserderived from our eFlow Technology platform and tailored for a specific medicinal product.
  • Since it is used to treat NTM patients LAMIRA extends the range of indications for which optimised eFlow Technology nebulisers are used.
  • ARIKAYCE is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension) and in the EU as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion.

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

Retrieved on: 
Thursday, October 22, 2020
Chronic lower respiratory diseases, Respiratory therapy, Health, Medical specialties, Clinical medicine, RTT, Aerosols, Nebulizer, Chronic obstructive pulmonary disease, Asthma, Respiratory disease, Cystic fibrosis

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Key Points: 
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • If successfully developed and approved, Verona Pharmas product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Ensifentrine is in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.

Global Pneumatic Nebulizers Market to 2027: Amid the COVID-19 Pandemic, the Market is Projected to Reach a Revised $837.8 Million

Retrieved on: 
Friday, October 9, 2020
Aerosols, Dosage forms, Medical equipment, Respiratory therapy, Nebulizer, Health, Compound annual growth rate, Medicine

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- The "Pneumatic Nebulizers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 9, 2020 /PRNewswire/ -- The "Pneumatic Nebulizers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Pneumatic Nebulizers estimated at US$649.5 Million in the year 2020, is projected to reach a revised size of US$837.8 Million by 2027, growing at a CAGR of 3.7% over the period 2020-2027.
  • Vented, one of the segments analyzed in the report, is projected to record 3.3% CAGR and reach US$337.1 Million by the end of the analysis period.
  • The U. S. Market is Estimated at $175.2 Million, While China is Forecast to Grow at 6.6% CAGR
    The Pneumatic Nebulizers market in the U. S. is estimated at US$175.2 Million in the year 2020.

Global Asthma and COPD Smart Inhalers Markets Report 2020 with Profiles of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharma - ResearchAndMarkets.com

Retrieved on: 
Friday, October 9, 2020
Health, Pharmaceutical, Dosage forms, Medicine, Health, Clinical medicine, Asthma, Respiratory therapy, Smoking cessation, Metered-dose inhaler, Inhaler, Dry-powder inhaler, Nebulizer

The current report offers a comprehensive picture of the smart inhalers market.

Key Points: 
  • The current report offers a comprehensive picture of the smart inhalers market.
  • Smart inhalers prescribed for the treatment of asthma and COPD are included in the scope of the study.
  • Digital companies merely provide the sensors to pharma companies; and pharma companies are the ones assembling smart inhalers and making them available.
  • Based on the product, the market is fragmented into dry powder inhaler (DPI)-based smart inhalers and metered-dose inhaler (MDI)-based smart inhalers.